Oxford Cancer Biomarkers partners with Mira Precision Health to advance its ToxNav® test for predicting patient toxicity to 5FU/capecitabine treatment in the USA
Dr. David Kerr, Founder and Director of the Board of OCB, and Professor of Cancer Medicine at Oxford University, commented, 'We developed our ToxNav test to identify cancer patients that have a high likelihood of undergoing extreme toxicity to 5FU/capecitabine treatment, which is one of the most widely used cancer drugs in the world. We have already clinically proven that ToxNav identifies patients that are susceptible to extreme toxicity and are excited to have partnered the test with Mira Precision, who have complementary expertise to advance ToxNav in the USA. We look forward to a long and productive relationship with Mira Precision as we advance ToxNav to widen its clinical utility in the USA and save more patient lives.'
Dr. Sandra Gunselman, Founder and CEO of Mira Precision Health, said, 'I founded Mira Precision Health with the vision of bringing the most innovative and personalized diagnostic solutions to healthcare providers and their patients. Our collaboration with Dr. Kerr and the renowned team at Oxford Cancer Biomarkers marks an exciting inflection point for Mira, allowing us to partner with globally-respected academic medical centers and deliver advanced precision medicine directly into clinical practice. Together, we're committed to significantly improving patient care and outcomes across the United States.'
Karen Merritt, Co-Founder of Advocates for Universal DPD/DPYD Testing, comments, 'I strongly support the partnership between Oxford Cancer Biomarkers and Mira Precision Health, as it represents a critical step toward safer, more comprehensive pretreatment DPYD screening to prevent avoidable toxicity and save lives.'
ToxNav® enhances clinical decision-making through comprehensive genetic profiling, aligning directly with recent NCCN Guidelines updates that recommend DPYD testing for colorectal cancer patients receiving fluoropyrimidine-based treatments. Shaun Peterson, VP of Sales and Marketing at Mira Precision Health, noted, 'The NCCN revision underscores the timely clinical importance of the Mira Precision ToxNav® Test in the US market. Backed by multiple peer-reviewed studies and CE-IVD certification in the UK, ToxNav® significantly improves patient outcomes, reduces healthcare costs, and advances equitable precision medicine. This partnership between Oxford Cancer Biomarkers and Mira Precision Health reinforces our commitment to personalized cancer care innovation.'
Michele Blair, Director of Economic Development for the City of Mason, said, 'We are excited to partner with Mira Precision Health to further science partnerships like ToxNav. Using the Mason Living Lab we have been able to connect an educated population with new and growing health technology to achieve faster commercialization. The new Mira Precision ToxNav® Test is an excellent addition to our portfolio of technology.'
About Oxford Cancer Biomarkers Ltd (OCB)
Oxford Cancer Biomarkers (OCB) is a spin-out from the University of Oxford, developing and commercialising a suite of molecular and AI-enabled diagnostic tools that harness the analytical capabilities of pharmacogenomic markers and digital pathology to optimise cancer treatment pathways. OCB continues to expand its portfolio with novel biomarkers and proprietary algorithms that enable clinicians to make personalized treatment recommendations based on real-world evidence, empowering patients to make better-informed decisions about their own cancer therapy. Its most recent investment came from Plutus Investments Group LLP, which is a multi-family office backing entrepreneurs in Europe and the USA, focused on Life Sciences, Biotech, Fintech, and Tech investments.
For more information, please visit www.oxfordbio.com.
About Mira Precision Health, Inc.
Mira Precision Health was founded to provide advanced molecular diagnostic testing directly to healthcare providers and communities. Inspired by the empowerment and strength symbolized by the name 'Mira,' Founder and CEO Dr. Sandra J. Gunselman envisioned reshaping precision medicine by equipping clinics, health systems, and independent providers with cutting-edge clinical genomics, pharmacogenomics expertise, and data informatics tools. Mira Precision Health is dedicated to enhancing clinical decision support, improving patient safety, and delivering personalized, data-driven healthcare solutions that significantly elevate patient outcomes.
For more information, please visit www.miraprecision.com
About The City of Mason BioHub
Recognized as a leader in Ohio and the Midwest, the City of Mason BioHub is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. With $600 million in new investment and more than 1,200 jobs announced in 2024 primarily in this sector, the City's Economic Development arm has created an unmatched model for scaling young growth companies. Through its proprietary Living Lab initiative, the City is able to leverage its diverse demographic population and scientific business community to scale young HealthTech companies, while improving personal health outcomes for residents. For more information about the City of Mason, visit www.whyMason.com or www.imagineMason.org.
For further information, please contact:
Oxford Cancer Biomarkers Ltd Tel: 0044 7976 708535
Mira Precision Health, Shaun Peterson, Vice President, Sales and Marketing, [email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/oxford-cancer-biomarkers-partners-with-mira-precision-health-to-advance-its-toxnav-test-for-predicting-patient-toxicity-to-5fucapecitabine-treatment-in-the-usa-302469984.html
SOURCE City of Mason
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Capital Clean Energy Carriers Corp. Announces Annual Meeting of Shareholders
ATHENS, Greece, Aug. 08, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) (the 'Corporation' or 'CCEC') has called an annual meeting of shareholders to be held at the Corporation's headquarters in Greece on September 22, 2025 at 11:30 am local time (the 'Annual Meeting'). Shareholders of record at the close of business on July 25, 2025 are entitled to receive notice of, and to vote at, the Annual Meeting, or any adjournments or postponements thereof. A cover letter, formal notice of the Annual Meeting, the Corporation's proxy statement and the accompanying Annual Report on Form 20-F are being sent to shareholders of the Corporation. Electronic copies of the materials are accessible on the Corporation's website at Following receipt of a proxy card, shareholders may vote their common shares by accessing . About Capital Clean Energy Carriers Corp. Capital Clean Energy Carriers Corp. (NASDAQ: CCEC), an international shipping company, is one of the world's leading platforms of gas carriage solutions with a focus on energy transition. CCEC's in-the-water fleet includes 15 high specification vessels, including 12 latest generation LNG/Cs and three legacy Neo-Panamax container vessels. In addition, CCEC's under-construction fleet includes six additional latest generation LNG/Cs, six dual-fuel medium gas carriers and four handy LCO2/multi-gas carriers, to be delivered between the first quarter of 2026 and the third quarter of 2027. Contact Details: Investor Relations / MediaBrian Gallagher EVP Investor RelationsTel. +44-(770) 368 4996 E-mail: Nicolas Bornozis/Markella KarraCapital Link, Inc. (New York)Tel. +1-212-661-7566E-mail: ccec@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business Wire
Freedom Holding Corp. Reports First Quarter Fiscal Year 2026 Financial Results
NEW YORK--(BUSINESS WIRE)--Freedom Holding Corp. (the 'Company') (NASDAQ: FRHC), a multinational diversified financial services holding company with a presence in 22 countries, today announced financial results for the first quarter of fiscal year 2026 ended June 30, 2025. Highlights during the quarter include the following: $533.4 million in total revenue, net, versus $455 million for the quarter ended June 30, 2024, a 17% increase Net income of $30.4 million, or $0.50 per diluted share, $0.51 per basic share Total assets of $9.7 billion Total customers across segments rose to 5.3 million at June 30, 2025 Added to the Russell 3000 ® Index on June 27, 2025 S&P Global Ratings revised its outlook to Positive from Stable and affirms Credit Ratings for Freedom KZ, Freedom EU, Freedom Global, and Freedom Bank KZ Fiscal First Quarter 2026 Financial Highlights: The Company recognized total revenue, net of $533.4 million in the fiscal 2026 first quarter, an increase of 17% from $455 million in the comparable prior-year period. Revenue rose at the brokerage, banking, and insurance segments. Insurance premiums earned, net of reinsurance rose by 18% to $153.3 million from last year's first quarter and the Company realized a net gain on trading securities of $45.6 million compared to a net loss of $52.1 million in last year's fiscal first quarter. The Company had a net gain on derivatives of $15.5 million in the fiscal 2026 first quarter, an increase of 24% from $12.5 million in last year's first quarter due to revaluation of currency swaps. The Company's total expense was approximately $492.9 million in fiscal 2026 first quarter as compared to $413.4 million in last year's first quarter. Net income was $30.4 million for the fiscal 2026 first quarter compared to $34.4 million in the first quarter of fiscal 2025. Basic and diluted earnings per share were $0.51 and $0.50, respectively, compared to $0.58 and $0.57 per share, respectively, in last year's first quarter. Weighted average common shares outstanding used to compute basic and diluted earnings per share for the quarter ended June 30, 2025 were 59.9 million and 61.1 million, respectively, and 59.3 million and 60.3 million, respectively, for the quarter ended June 30, 2024. Total assets were $9.7 billion on June 30, 2025, compared to $9.9 billion as of the fiscal 2025 year ended March 31, 2025. Continuing the Growth and Evolution of our Business Model 'Our results for the fiscal 2026 first quarter reflect the continuing growth and evolution of our business model,' said Timur Turlov, the Company's founder and chief executive officer. 'We have expanded our product portfolio, embraced the digital transformation of our platform, and strengthened our market presence. We are also elevating our profile in the investment community, as reflected by our inclusion in the Russell 3000® Index on June 27, 2025. We remain ever-grateful for the dedication and hard work of our 10,054 employees in 231 offices around the world.' Mr. Turlov noted the Company's success in transforming into a one-stop shop, multi-point financial ecosystem that allows clients to manage their diverse financial needs in partnership with a single, trusted provider. He continued, 'Our commitment to providing the highest level of client service and accountability, including the continuing success of our Super App, has allowed us to expand our client base to more than 5.3 million across our three primary segments, representing a nearly 5% increase from March 31, 2025. Our strong financial position will support our growth objectives for fiscal 2026, with a focus on continuing our investments in digital infrastructure and AI to build out the Freedom services portfolio.' Additional Fiscal First Quarter 2026 highlights Brokerage: Revenue increased to $176.3 million from $174.9 million, driven by increases in fee and commission income, net gain on trading securities, and interest income, partially offset by a decrease in net (loss)/gain on foreign exchange operations and lower other income. Total retail brokerage clients rose to 725,000 as of June 30, 2025 compared to 683,000 as of March 31, 2025. Brokerage services were offered at 44 offices as of June 30, 2025. Banking: Revenue increased by 60% to $146.2 million from $91.2 million, driven primarily by an increase of net gain in trading securities, partially offset by lower commission income, which was primarily driven by active use by customers of a cashback-based loyalty program. The loyalty program is leveraged to effectively reduce transaction costs for customers by supporting our customer base expansion and increasing engagement across the ecosystem. Total banking clients rose to 2,927,000 as of June 30, 2025, up from 2,515,000 as of March 31, 2025. Banking services were offered at 30 offices as of June 30, 2025. Insurance: Revenue rose by 18% to $174.0 million from $147.3 million, driven by improved insurance premiums earned, net of reinsurance from written insurance premiums due to the expansion of the Company's insurance operations such as pension annuity and accident insurance. Total insurance clients rose to 1,396,000 as of June 30, 2025, from 1,170,000 as of March 31, 2025. Insurance services were offered at 57 offices as of June 30, 2025. Other Segments: Revenue declined to $36.9 million from $41.6 million as additional lifestyle benefits were added for customers as we invest in and develop the telecom business as part our long-term strategic planning. Acquisition of Astel Group Ltd On April 30, 2025, the Company acquired 100% interest in Astel Group Ltd. Astel Group Ltd. is a provider of digital solutions and telecommunications services, and ranks among the largest telecom operators in Kazakhstan. Astel Group Ltd provides advanced IT solutions including information security and cloud services. The purpose of the acquisition of Astel Group Ltd was to use the acquired assets and licenses to develop our telecommunications business. As of April 30, 2025, the date of the acquisition of Astel Group Ltd, the fair value of net assets of Astel Group Ltd was $20.6 million. The total purchase price was $22.3 million. About Freedom Holding Corp. Freedom Holding Corp., a Nevada corporation, is a diversified financial services holding company conducting securities brokerage, investment research, investment counseling, securities dealing, commercial banking and insurance products through its subsidiaries, operating under the name Freedom Finance in Europe and Central Asia, and Freedom Capital Markets in the United States. Through its subsidiaries, Freedom Holding Corp. employs more than 10,054 people and is a professional participant in the Kazakhstan Stock Exchange, the Astana International Exchange, the Republican Stock Exchange of Tashkent, International Trading System Limited, Armenia Stock Exchange, Kyrgyz Stock Exchange, the Uzbek Republican Currency Exchange and is a member of the New York Stock Exchange and the Nasdaq Stock Exchange. Freedom Holding Corp.'s common shares are registered under the United States Securities Exchange Act of 1934 and are traded under the symbol FRHC on the Nasdaq Capital Market, operated by Nasdaq, Inc. The Company has its main market of operations in Kazakhstan and has operations through its subsidiaries in 22 countries. To learn more about Freedom Holding Corp., visit Cautionary Note Regarding Forward-Looking Statements This release contains "forward-looking" statements within the meaning of section 21E of the Securities Exchange Act of 1934. All forward-looking statements are subject to uncertainty and changes in circumstances. In some cases, forward-looking statements can be identified by terminology such as "expect," "new," "plan," "seek," and "will," or the negative of such terms or other comparable terminology and include statements relating to our plans, intentions and expectations including our plans to enter the telecommunications market, our expectations with respect to further years and other non-historical statements. Forward-looking statements are not guarantees of future results or performance and involve risks, assumptions, and uncertainties that could cause actual events or results to differ materially from the events or results described in, or anticipated by, the forward-looking statements. Factors that could materially affect such forward-looking statements include economic, business, and regulatory risks and other factors including those identified in the Company's periodic and current reports filed with the U.S. Securities and Exchange Commission. All forward-looking statements are made only as of the date of this release and the Company assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Website Disclosure Freedom Holding Corp. intends to use its website, as a means for disclosing material non-public information and for complying with U.S. Securities and Exchange Commission Regulation FD and other disclosure obligation. FREEDOM HOLDING CORP. (All amounts in thousands of United States dollars, unless otherwise stated) Three Months Ended June 30, 2025 2024 Revenue: Fee and commission income $ 107,642 $ 115,489 Net gain/(loss) on trading securities 45,602 (52,102 ) Interest income 198,571 226,004 Insurance premiums earned, net of reinsurance 153,257 129,408 Net (loss)/ gain on foreign exchange operations (12,893 ) 8,089 Net gain on derivatives 15,459 12,494 Sales of goods and services 17,224 5,220 Other income 8,561 10,397 TOTAL REVENUE, NET $ 533,423 $ 454,999 Expense: Fee and commission expense $ 84,871 $ 80,147 Interest expense 113,410 145,718 Insurance claims incurred, net of reinsurance 80,285 47,309 Payroll and bonuses 93,101 57,524 Professional services 13,024 7,268 Stock compensation expense 23,054 10,615 Advertising and sponsorship expense (including for the three months ended $5,513 and $2,045 from related parties) 24,463 21,896 General and administrative expense 41,975 40,410 Allowance for/(recovery of) expected credit losses 4,822 (1,770 ) Cost of sales 13,903 4,284 TOTAL EXPENSE $ 492,908 $ 413,401 INCOME BEFORE INCOME TAX 40,515 41,598 Income tax expense (10,119 ) (7,339 ) NET INCOME $ 30,396 $ 34,259 Less: Net loss attributable to non-controlling interest in subsidiary — (141 ) NET INCOME ATTRIBUTABLE TO COMMON SHAREHOLDERS $ 30,396 $ 34,400 OTHER COMPREHENSIVE INCOME Change in unrealized gain on investments available-for-sale, net of tax effect 2,998 3,374 Reclassification adjustment for net realized loss/(gain) on available-for-sale investments disposed of in the period, net of tax effect 174 (18 ) Foreign currency translation adjustments (41,804 ) (65,811 ) OTHER COMPREHENSIVE LOSS (38,632 ) (62,455 ) $ (8,236 ) $ (28,196 ) — (141 ) $ (8,236 ) $ (28,055 ) EARNINGS PER COMMON SHARE (In U.S. dollars): Earnings per common share - basic 0.51 0.58 Earnings per common share - diluted 0.50 0.57 Weighted average number of shares (basic) 59,853,479 59,258,085 Weighted average number of shares (diluted) 61,057,627 60,255,593 Expand
Business Wire
2 days ago
- Business Wire
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock options were granted on August 7, 2025. The stock options have an exercise price of $1.30 per share, which is equal to the closing price of Geron common stock on the grant date and have a ten-year term. 7,000,000 of the stock options vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of commencement of his employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. 4,000,000 of the stock options vest over four years, with 25% of the shares underlying the options vesting on the one-year anniversary of commencement of his employment and the remaining shares vesting over the following 36 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. The stock options were granted by Geron's Board of Directors (the 'Board'), upon recommendation of the Compensation Committee of the Board, in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron's 2018 Inducement Award Plan and the form of stock option agreement under the plan. About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit or follow us on LinkedIn.
